Abstract:Gastric cancer is one of the most common malignant tumors, and chemotherapy is the main treatment for advanced gastric cancer. However, chemotherapy resistance leads to treatment failure and poor prognosis in patients with gastric cancer. Multidrug resistance (MDR) is a major challenge that needs to be overcome in chemotherapy. According to recent research, ferroptosis activation is crucial for tumor therapeutic strategies. In this work, we explored the solution to chemoresistance in gastric cancer by investigating the effects of the Chinese medicine monomer baicalin on ferroptosis. Baicalin with different concentrations was used to treat the parent HGC27 and drug-resistant HGC27/L cells of gastric cancer. Cell viability was measured by CCK8, and synergistic effects of baicalin combined with oxaliplatin were evaluated using Synergy Finder software. The effects of baicalin on organelles and cell morphology were investigated using projective electron microscopy. Iron concentration, MDA production and GSH inhibition rate were measured by colorimetry. ROS accumulation was detected by flow cytometry. The ferroptosis-related genes (IREB2, TfR, GPX4, FTH1), P53, and SLC7A11 were analysed by Western blot, and the expression differences of the above proteins between pretreatment and pretreatment of different concentrations of baicalin, were assayed in both parental HGC27 cells and Oxaliplatin-resistant HGC27/L cells. Mechanically, Baicalin disrupted iron homeostasis and inhibits antioxidant defense, resulting in iron accumulation, lipid peroxide aggregation, and specifically targeted and activated ferroptosis by upregulating the expression of tumor suppressor gene p53, thereby activating the SLC7A11/GPX4/ROS pathway mediated by it. Baicalin activates ferroptosis through multiple pathways and targets, thereby inhibiting the viability of oxaliplatin-resistant gastric cancer HGC27/L cells and enhancing the sensitivity to oxaliplatin chemotherapy.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is: to explore whether baicalin can improve the sensitivity of gastric cancer cells to the chemotherapeutic drug oxaliplatin, especially for the oxaliplatin - resistant gastric cancer cell line HGC27/L, and to explore its potential mechanisms, especially whether baicalin achieves this effect by inducing ferroptosis. ### Background and the Importance of the Problem Gastric cancer is the fourth most common malignant tumor globally. Chemotherapy is the main treatment method for advanced gastric cancer. However, chemotherapy resistance leads to treatment failure and poor prognosis of patients. Multidrug resistance (MDR) is a major challenge to be overcome in chemotherapy. Recent studies have shown that activating ferroptosis is crucial in tumor treatment strategies. Therefore, it is of great clinical significance to study whether baicalin can overcome the chemotherapy resistance of gastric cancer cells by activating ferroptosis. ### Research Objectives 1. **Improve Chemotherapy Sensitivity**: To study whether baicalin can enhance the sensitivity of the oxaliplatin - resistant gastric cancer cell HGC27/L to oxaliplatin. 2. **Induce Ferroptosis**: To explore whether baicalin can inhibit the growth of gastric cancer cells by inducing ferroptosis. 3. **Mechanism Research**: To reveal the specific mechanism of baicalin - induced ferroptosis, especially by up - regulating p53 gene expression and activating the SLC7A11/GPX4/ROS pathway. ### Experimental Methods - **Cell Lines and Reagents**: Use the human gastric cancer cell line HGC - 27 and its resistant cell line HGC27/L for experiments. - **Cell Viability Assay**: Determine cell viability by the CCK - 8 method to evaluate the cytotoxicity of baicalin and oxaliplatin used alone or in combination. - **Iron Metabolism and Antioxidant Defense Detection**: Determine the MDA content, total iron ion concentration and GSH inhibition rate by colorimetry, and detect ROS accumulation by flow cytometry. - **Mitochondrial Membrane Potential Assay**: Use the fluorescent probe JC - 1 to observe the changes in mitochondrial membrane potential by confocal microscopy. - **Protein Expression Analysis**: Detect the expression changes of ferroptosis - related genes (IREB2, TfR, GPX4, FTH1), p53 and SLC7A11 by Western blot. ### Main Findings - **Cell Viability Inhibition**: Baicalin significantly inhibited the viability of HGC27 and HGC27/L cells at different concentrations in a time - and dose - dependent manner. - **Synergistic Effect**: When baicalin was used in combination with oxaliplatin, the IC50 values of HGC27 and HGC27/L cells were significantly reduced, showing a synergistic anti - tumor effect. - **Ferroptosis Activation**: After baicalin treatment, the MDA content, total iron ion concentration and ROS accumulation in HGC27 and HGC27/L cells increased significantly, and the mitochondrial membrane potential decreased. These changes are in line with the characteristics of ferroptosis. - **Mechanism Analysis**: Baicalin specifically activates ferroptosis by disrupting iron homeostasis and inhibiting antioxidant defense, resulting in iron accumulation and lipid peroxidation aggregation. In addition, baicalin up - regulates the expression of the p53 gene and activates the SLC7A11/GPX4/ROS pathway, thereby enhancing the sensitivity of gastric cancer cells to oxaliplatin. ### Conclusion This study shows that baicalin can improve the sensitivity of oxaliplatin - resistant gastric cancer cells to chemotherapeutic drugs by inducing ferroptosis, providing new strategies and ideas for overcoming chemotherapy resistance in gastric cancer.

Baicalin enhances the chemotherapy sensitivity of oxaliplatin-resistant gastric cancer cells by activating p53-mediated ferroptosis

Baicalin enhances the efficacy of 5-Fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis

Baicalin induces ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4 regulatory axis

[Baicalin induces ferroptosis in HepG2 cells by inhibiting ROS-mediated PI3K/Akt/FoxO3a signaling pathway]

Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1

Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2/STAT3/GPX4 axis

Baicalin promotes the sensitivity of NSCLC to cisplatin by regulating ferritinophagy and macrophage immunity through the KEAP1-NRF2/HO-1 pathway

Baicalin induces ferroptosis in oral squamous cell carcinoma by suppressing the activity of FTH1

Baicalin protects against hepatocyte injury caused by aflatoxin B1 via the TP53-related ferroptosis Pathway

Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis

Ferroptosis-related oxaliplatin resistance in multiple cancers: Potential roles and therapeutic Implications

NOLC1 Suppresses Immuno-chemotherapy by Inhibiting p53-mediated Ferroptosis in Gastric Cancer

Plumbagin induces ferroptosis in colon cancer cells by regulating p53-related SLC7A11 expression

Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin

Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6

Pretreatment of baicalin and wogonoside with glycoside hydrolase: a promising approach to enhance anticancer potential.

Induction of ferroptosis by brucine suppresses gastric cancer progression through the p53-mediated SLCA711/ALOX12 axis

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways

LTBP2 Knockdown Promotes Ferroptosis in Gastric Cancer Cells through p62-Keap1-Nrf2 Pathway

Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling